Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5570 - Surgery of the primary tumor for de novo metastatic breast cancer: the controversy continues.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Surgical Oncology

Tumour Site

Breast Cancer

Presenters

Borja López de San Vicente

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

B. López de San Vicente, E. Galve Calvo, A. Zumarraga, F. Pikab ea, J.F. Arango Arteaga, M. López Santillan, C. Figaredo, M.A. Sala Gonzalez, M. Nuño Escolastico, P. Novas Vidal, J. Legaspi, P. Martinez del Prado

Author affiliations

  • Medical Oncology, Hospital Universitario Basurto, 48013 - Bilbao/ES
More

Resources

Abstract 5570

Background

De novo metastatic breast cancer (dnMBC) represents 6–10% of breast cancer. Due to its incurability, dnMBC is generally treated with systemic therapies to achieve disease control and reduce tumor-related symptoms. The need for radical loco-regional treatment and its consequent benefit in this setting remains still controversial. Meta-analysis of retrospective studies and prospective randomized studies did not report a clear survival benefit. The aim of this study was to analyze the impact of surgery to primary tumor (PT) in patients (pts) presenting with dnMBC.

Methods

Between Feb 2006-Oct 2015 we performed a retrospective chart review to 129 consecutive pts who attended our hospital with dnMBC. Descriptive, Kaplan-Meier and Cox regression analyses were carried out using SPSS version 23.0.

Results

A total of 129 pts. were analyzed. Median age was 68 years (range: 20-95), 59 pts (46%) had single organ metastasis, and their distribution according to the predominant site of disease was: skin/soft tissue 42 pts (33%), bone 87 pts (67%) and visceral 85 pts (66%). Surgery (S) of the PT was done in 32 pts (25%), 24 was radical procedures, 8 palliative and besides, 27 pts underwent axillary dissection. Initial S treatment was the choice for 29 pts. In the S group single organ disease was present in 66% vs 39% non-S group. Metastatic sites were: 50% vs 71% visceral, 44% vs 21% with bone metastasis in the S vs non-S group respectively. With a median follow-up of 2 years (SD 2.20), the 5-yr overall survival (OS) was 11.64% in the entire de novo MBC population, with a median OS of 36 m in the S-group vs 21 m. in the non-S-group (HR 1.46 p = 0.081). Subgroup analyses did not show a benefit of PT surgery in OS regardless of the number of metastasis and site of disease, and BC subtypes. The multi-adjusted HR for surgery was 0.14 (p = 0.188). The multivariate Cox regression analysis model included the site of disease (p = 0.971), the histopathologic grade (p = 0.876) and the hormone receptor status (p = 0.003).

Conclusions

In our series, surgical treatment of the primary tumor in patients with de novo metastatic breast cancer did not show a benefit in overall survival. Results of ongoing randomized trials are needed.

Clinical trial identification

Legal entity responsible for the study

Medical Oncology Service, Basurto University Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.